Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T01:41:57.274Z Has data issue: false hasContentIssue false
  • English
  • Français

Using the upper buttocks as a subcutaneous site for treprostinil infusion in children with pulmonary artery hypertension

Published online by Cambridge University Press:  26 May 2020

Hiroshi Ono Open the ORCID record for Hiroshi Ono [Opens in a new window] ,
Nobuyuki Yotani  and
Hitoshi Kato
Hiroshi Ono*
Affiliation:
Division of Cardiology, National Center for Child Health and Development, Tokyo, Japan
Nobuyuki Yotani
Affiliation:
Division of Palliative Care, National Center for Child Health and Development, Tokyo, Japan
Hitoshi Kato
Affiliation:
Division of Cardiology, National Center for Child Health and Development, Tokyo, Japan
*
Author for correspondence: Hiroshi Ono, Division of Cardiology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo157-8535, Japan. Tel: +81-3-3416-0181; Fax: +81-3-3416-2222. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

A 14-year-old boy was receiving subcutaneous infusions of treprostinil for pulmonary artery hypertension. Because he had severe infusion site pain in the lower abdomen, we changed his infusion site to the upper buttocks, adding some analgesics. His pain improved gradually. This change may be an effective method for reducing infusion site pain in subcutaneous treprostinil therapy, particularly in children.

Keywords

Treprostinilinfusion site painbuttocks
Type
Brief Report
Information
Cardiology in the Young , Volume 30 , Issue 7 , July 2020 , pp. 1024 - 1025
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Levy, M, Del Cerro, MJ, Nadaud, S, et al.Efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol 2018; 264: 153–157.CrossRefGoogle ScholarPubMed
Olson, E, Lusk, LA, Fineman, JR, Robertson, L, Keller, RL.Short-term treprostinil use in infants with congenital diaphragmatic hernia following repairs. J Pediatr 2015; 167: 762–764.CrossRefGoogle Scholar
Skoro-Sajer, N, Gerges, C, Balint, OH, et al.Subcutaneous treprostinil in congenital heart disease related pulmonary arterial hypertension. Heart 2018; 104: 1195–1199.CrossRefGoogle ScholarPubMed
Barst, RJ, Galie, N, Naeije, R, et al.Long-term outcome in pulmonary arterial hypertension patients treated with SubQ treprostinil. Eur Respir J 2006; 28: 1195–1203.CrossRefGoogle Scholar
Mathier, MA, McDevitt, S, Saggar, R.Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant 2010; 29: 1210–1217.CrossRefGoogle ScholarPubMed
Lang, I, Gomez-Sanchez, M, Kneussl, M, et al.Efficacy of long-term SubQ treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129: 1636–1643.CrossRefGoogle Scholar